Kyle Jacoby

发表

Membrane Proteases and Aminoglycoside Antibiotic Resistance

C. Manoil, A. Hinz, Samuel A. Lee, 2011, Journal of bacteriology.

TALEN-Mediated Gene Editing of HBG in Human Hematopoietic Stem Cells Leads to Therapeutic Fetal Hemoglobin Induction

I. Bernstein, A. Scharenberg, D. Rawlings, 2018, Molecular therapy. Methods & clinical development.

In Vivo Outcome of Homology-Directed Repair at the HBB Gene in HSC Using Alternative Donor Template Delivery Methods

A. Scharenberg, D. Rawlings, S. Lotti, 2019, Molecular therapy. Nucleic acids.

Membrane Proteases and Aminoglycoside Antibiotic Resistance (cid:1) †

C. Manoil, A. Hinz, Samuel A. Lee, 2011 .

Coupling endonucleases with DNA end–processing enzymes to drive gene disruption

Sarah K. Baxter, Michael T. Certo, A. Lambert, 2012, Nature Methods.

Non-viral precision T cell receptor replacement for personalized cell therapy

Katie M. Campbell, D. Baltimore, J. Sosman, 2022, Nature.

Talen Mediated Therapeutic Gene Editing Strategy for ß-Hemoglobinopathies

I. Bernstein, A. Scharenberg, D. Rawlings, 2017 .

Contact‐dependent growth inhibition requires the essential outer membrane protein BamA (YaeT) as the receptor and the inner membrane transport protein AcrB

S. Aoki, T. Silhavy, D. Low, 2008, Molecular microbiology.

Tapping natural reservoirs of homing endonucleases for targeted gene modification

Ryo Takeuchi, Kyle Jacoby, Russell J. Dickson, 2011, Proceedings of the National Academy of Sciences.

Neoantigen-targeted CD8^+ T cell responses with PD-1 blockade therapy

O. Griffith, M. Griffith, A. Ribas, 2023, Nature.

High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins.

Kyle Jacoby, Nicholas A. Popp, David J Rawlings, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

pEVL: A Linear Plasmid for Generating mRNA IVT Templates With Extended Encoded Poly(A) Sequences

A. Scharenberg, D. Rawlings, S. Burleigh, 2016, Molecular therapy. Nucleic acids.

Abstract 4783: Highly efficient, non-viral precision genome engineering for the generation of personalized neoepitope-specific adoptive T cell therapies

B. Sennino, S. Mandl, A. Litterman, 2019, Experimental and Molecular Therapeutics.

Abstract 1433: NeoTCR-P1, a novel neoepitope-specific adoptive cell therapy, consists of T cells with ‘younger’ phenotypes that rapidly proliferate and kill target cells upon recognition of cognate antigen

B. Sennino, S. Mandl, A. Litterman, 2019, Clinical Research (Excluding Clinical Trials).

Abstract 1435: An ultra-sensitive and high-throughput technology (imPACT) for the identification and isolation of intrinsic and emergent neoepitope-specific T cells from the peripheral blood and TILs of cancer patients

B. Sennino, S. Mandl, Salemiz Sandoval, 2019, Clinical Research (Excluding Clinical Trials).

Discovering and Characterizing New Homing Endonucleases for Genome Engineering

Kyle Jacoby, 2013 .

Characterization of homing endonuclease binding and cleavage specificities using yeast surface display SELEX (YSD-SELEX)

A. Lambert, A. Scharenberg, Kyle Jacoby, 2016, Nucleic acids research.

Homing endonuclease target determination using SELEX adapted for yeast surface display.

A. Scharenberg, Kyle Jacoby, 2014, Methods in molecular biology.

Expanding LAGLIDADG endonuclease scaffold diversity by rapidly surveying evolutionary sequence space

Michael T. Certo, B. Shen, B. Stoddard, 2012, Nucleic acids research.

1478 A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells

D. Baltimore, J. Sosman, A. Ribas, 2022, Late-Breaking Abstracts.